| Literature DB >> 31366939 |
Lenka Micenková1, Juraj Bosák2, Jiri Kucera3, Matěj Hrala2, Tereza Dolejšová4, Ondrej Šedo5, Dirk Linke6, Radovan Fišer4, David Šmajs7.
Abstract
Colicin production in Escherichia coli (E. coli) strains represents an important trait with regard to microbial survival and competition in the complex intestinal environment. A novel colicin type, colicin Z (26.3 kDa), was described as a product of an original producer, extraintestinal E. coli B1356 strain, isolated from the anorectal abscess of a 17 years-old man. The 4,007 bp plasmid (pColZ) was completely sequenced and colicin Z activity (cza) and colicin Z immunity (czi) genes were identified. The cza and czi genes are transcribed in opposite directions and encode for 237 and 151 amino acid-long proteins, respectively. Colicin Z shows a narrow inhibitory spectrum, being active only against enteroinvasive E. coli (EIEC) and Shigella strains via CjrC receptor recognition and CjrB- and ExbB-, ExbD-mediated colicin translocation. All tested EIEC and Shigella strains isolated between the years 1958-2010 were sensitive to colicin Z. The lethal effect of colicin Z was found to be directed against cell wall peptidoglycan (PG) resulting in PG degradation, as revealed by experiments with Remazol Brilliant Blue-stained purified peptidoglycans and with MALDI-TOF MS analyses of treated PG. Colicin Z represents a new class of colicins that is structurally and functionally distinct from previously studied colicin types.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31366939 PMCID: PMC6668396 DOI: 10.1038/s41598-019-47488-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Bacterial strains and plasmids used in this study.
| Bacterial strains or plasmids | Genotype and/or phenotype | Source |
|---|---|---|
| Original producer of new colicin type Z; extraintestinal pathogenic | This laboratory | |
| F–
| Thermo Fisher Scientific | |
| F−
| Lucigen | |
| F′{lacIq Tn10 (TetR)} | Thermo Fisher Scientific | |
| Δ | This laboratory | |
| Δ | This laboratory | |
| Δ | This laboratory | |
| Δ | This laboratory | |
| Δ | This laboratory | |
| Δ | This laboratory | |
| Δ | This laboratory | |
| Control strain - wild type | Keio collection | |
| Δ | This laboratory | |
| Δ | This laboratory | |
| pBAD/HisB | Cloning vector; | Thermo Fisher Scientific |
| Colicin Z activity and immunity | ||
| pColZ46 | pBAD/HisB with | This laboratory |
| pColZ99 | pBAD/HisB with | This laboratory |
| Colicin Z receptor | ||
| pColZ91 | pBAD/HisB with | This laboratory |
| pColZ93 | pBAD/HisB with | This laboratory |
| pColZ95 | pBAD/HisB with | This laboratory |
| pColZ97 | pBAD/HisB with | This laboratory |
| pColZ123 | pBAD/HisB with | This laboratory |
Figure 1(A) A schematic map of plasmid ColZ (4,007 bp). Unique BamHI restriction site was used as a reference point in the pColZ genetic map. The localization and polarity of predicted genes and the position of the putative origin of replication (ori) are indicated. The colicin Z activity (cza) and immunity genes (czi) are shown as gray arrows. (B) Putative promoter regions (−10 and −35), SOS box, and ribosome binding site sequences (S.D.) are indicated. Numbers correspond to positions in pColZ. (C) A domain organization of colicin Z. The N-terminal part of colicin Z protein sequence showed similarity to the colicins A and D translocation domain. Homology to non-lysosomal glucosylceramidase and metalloprotease was seen in the central part of colicin Z and the T-terminal part showed homology to colicin JS. Functional domains of colicin JS have not been previously described, but colicins Z and JS use the same receptor molecule, i.e., protein CjrC. *predicted translocation, activity, and receptor binding domains **sequence identity (%).
Characterization of pColZ predicted open reading frames (ORFs) encoding polypeptides longer than 50 amino acids.
| ORF | Strand | Frame | Start | Stop | Lenght (aa) | Protein similarity | UniProt | Organism | No. of aa aligned | Identity (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | + | 1 | 13 | 168 | 51 | Probable plasmid replication initiation protein | A0A2X6I7G5 | 39 | 56.4 | |
| 2 | − | 1 | 590 | 348 | 80 | Rep protein | A0A152X0V5 | 76 | 93.4 | |
| 3 | + | 3 | 441 | 611 | 56 | Plasmid replication protein | A0A2Y0VLC8 | 50 | 96.0 | |
| 4 | - | 3 | 897 | 667 | 76 | Plasmid mobilization protein MobB | A0A2Y8HSM0 | 45 | 36.5 | |
| 5 | + | 2 | 809 | 961 | 50 | MobB | M1L7H5 | 35 | 45.7 | |
| 6 ( | + | 1 | 1114 | 1827 | 237 | Colicin-A protein | U2N7R4 | 118 | 39.2 | |
| Colicin type 7 (Cja) | A0A0T9U2E6 | 89 | 44.9 | |||||||
| 7 | − | 1 | 1310 | 1146 | 54 | Colicin-A protein | U2N7R4 | 54 | 32.8 | |
| 8 | − | 1 | 1928 | 1734 | 64 | Uncharacterized protein | U5TRH2 | 30 | 76.7 | |
| 9 ( | − | 3 | 2346 | 1891 | 151 | Uncharacterized protein | A0A1X1EJN9 | 145 | 33.8 | |
| 10 | + | 2 | 2027 | 2209 | 60 | Uncharacterized protein | A0A1X0VY47 | 56 | 35.7 | |
| 11 | − | 3 | 2811 | 2539 | 90 | Helix-turn-helix domain-containing protein | A0A2T1MMQ2 | 74 | 91.9 | |
| 12 | − | 3 | 3885 | 3346 | 179 | Firmicute plasmid replication protein | E9TMC2 | 175 | 98.3 |
Colicin Z activity spectrum and prevalence of cza gene in the sets of E. coli strains.
| Genus/Strain | No. of strains | Sensitivity to colicin Z |
|---|---|---|
| E. coli strains | No. osf strains | Prevalence of cza gene (%) |
| 3 | no | |
| 3 | no | |
| 1 | no | |
| Enterohemorrhagic | 152 | no |
| Enterotoxigenic | 200 | no |
| ESBL-producing | 4 | no |
| commensal | 46 | no |
| enteroinvasive | 2 | yes (all sensitive) |
| 2 | no | |
| 1 | no | |
| 1 | no | |
| 3 | no | |
| 1 | no | |
| 3 | no | |
| 1 | no | |
| 2 | no | |
| Shiga-toxigenic | 101 | no |
| 36 | yes (all sensitive) | |
| 1 | no | |
| Commensal | 95 | n.d.** |
| Uropathogenic | 95 | n.d. |
| Extraintestinal pathogenic | 95 | n.d. |
| Intestinal pathogenic* | 95 | n.d. |
| Veterinary | 95 | n.d. |
*Intestinal E. coli isolated from patients with diagnosed infectious and parasitic diseases
**N.d. not detected.
Sensitivity of E. coli DH10B cells carrying different plasmids to colicin Z.
| Plasmids | Genes introduced | Colicin Z sensitivity |
|---|---|---|
| None | — | resistant |
| pColZ91 | resistant | |
| pColZ93 | resistant | |
| pColZ95 | resistant | |
| pColZ97 | resistant | |
| pColZ123 | sensitive |
Figure 2Purification of colicin Z and its biological activity. (A) Purification of colicin Z containing an N-terminal histidine tag by using Ni Sepharose 6 Fast Flow column. Lane 1, low-molecular-weight protein standard (PageRuler Prestained Protein Ladder, Fermentas); lane 2, purified colicin Z with an N-terminal histidine tag. Full-length gel is included in a Supplementary Fig. S3. (B) Inhibition zone of the original producer of colicin Z (E. coli B1356), against the E. coli O164 indicator strain and the antibacterial activity of purified N-terminal His-tagged colicin Z (tested by spotting of 10-fold serial dilutions) on the E. coli O164 strain. The biological activity of purified colicin Z was 104 arbitrary units.
Figure 3(A) Absorbance of dye released from the samples of RBB-stained peptidoglycan incubated (24 h at 37 °C) with active purified colicin Z, lysozyme and controls ( PG + distilled water; PG + purified control E. coli TOP10F′ harboring only cloning vector pBAD/HisB; and PG + denatured purified colZ) measured at 595 nm. (B) Absorbance of dye released from control samples of RBB-PG and from RBB-PG treated with denatured or active colicin Z. A statistically significant difference was observed between the activity of denatured and active colicin Z.
Figure 4MALDI-TOF MS analysis of peptidoglycan cleavage products following incubation with active and denatured colicin Z. In the MALDI-TOF MS profiles of control PG and PG incubated with denatured colicin Z (0.1 mg/ml), no difference was detected during the time-points tested (1 min, 5 min, and 1 hour). In the samples containing PG incubated with active colicin Z (0.1 mg/ml), a variety of new peaks in the range from 2500 to 14000 m/z were detected after 5 min of incubation. These peaks are consistent with the different products of peptidoglycan degradation.